LV-CMV-Cre-GFP-Puro

SKU:BHV22000014
New Research Validated
Overview
Click light‑blue chips for details
LV-CMV-Cre-GFP-Puro is a pre-packaged, ready-to-use lentiviral vector from SignaGen Laboratories that expresses Cre under the CMV promoter with GFP as the reporter and carries a puromycin resistance marker. Suitable for stable transduction of dividing and non-dividing cells in vitro and in vivo.
Promoter CMV
Reporter/Tag GFP
Transgene Cre
Expression Regulation Constitutive
Selection Marker Puromycin
Titer >1E+9 TU/mL
Biosafety Level BSL-2
Options selector
Catalog no. Size
SL100277-25UL 25 uL
SL100277-25ULX2 25 uL x 2
Available Options

Select the variant that best fits your experiment. Availability and lead time may vary by option.

  • Options: Size: 25 uL; 25 uL x 2
  • Lead time: options listed in "Availability Content"; other statuses may take longer.
  • Storage: Store at -80°C; avoid repeated freeze-thaw cycles.
  • Shipping: Ships on dry ice.
  • Upon receipt: store at recommended temperature as soon as possible; avoid repeated freeze-thaw cycles.
  • Sales terms and conditions: Please review prior to ordering.
Field Specification
Alternative names LV-CMV-Cre-GFP-Puro | LV-CMV-Cre-GFP-PGK-Puro | CMV-Cre-GFP Lentivirus
Applications
  • Lentiviral Transduction
  • Genetic Driver / Recombination
Purity In vivo grade and OK for both in vitro tissue culture infection and in vivo injection * Concentrated via PEG precipitation followed by ultra-centrifugation at 25000 rpm
Titer >1E+9 TU/mL
Transgene Cre
Promoter CMV
Reporter/Tag GFP
Expression regulation Constitutive
Selection marker Puromycin
Biosafety level BSL-2
Storage buffer PBS
Catalog no. (Mfr.) SL100277
Main SKU BHV22000014
Lentiviral Vector

Vector Overview

Cre recombinase is a type I topoisomerase from bacteriophage P1 that catalyzes the site-specific recombination of DNA between loxP sites. Cre recombinase is used as a tool to genetically modify genes, such as to delete a segment of DNA flanked by loxP sites in cells or experimental animals. This pre-made lentivirus LV-CMV-Cre-GFP-Puro expresses Cre recombinase fusion with GFP under the CMV promoter with co-expression of puromycin resistance under the PGK promoter. Ready to use format.

Technical Details

Catalog No. SL100277
Promoter CMV
Transgene Cre
Reporter / Tag GFP
Expression Regulation Constitutive
Selection Marker Puromycin
Titer >1E+9 TU/mL
Storage Buffer PBS
Purity / Grade In vivo grade and OK for both in vitro tissue culture infection and in vivo injection * Concentrated via PEG precipitation followed by ultra-centrifugation at 25000 rpm
Biosafety Level BSL-2
Sizes 25 uL; 25 uL x 2

Applications

  • Lentiviral Transduction: stable delivery of the cassette into dividing and non-dividing cells for long-term expression.
  • Genetic Driver / Recombination: recombinase-mediated activation or excision of matching conditional alleles and DIO reporters.

Biosafety

LV-CMV-Cre-GFP-Puro is a pre-packaged lentiviral vector classified as BSL-2. Handle in a certified biosafety cabinet under institutional BSL-2 practices, decontaminate all contact surfaces and waste, and follow local regulations for viral vector work.

Safety & Handling

Store at -80°C; avoid repeated freeze-thaw cycles. Ships on dry ice. Supplied in PBS. For research use only; not for diagnostic or therapeutic use.

Q.What biosafety level is required for LV-CMV-Cre-GFP-Puro?
A.LV-CMV-Cre-GFP-Puro is a lentiviral vector handled at BSL-2. Work in a certified biosafety cabinet, wear appropriate PPE and decontaminate all waste; institutional biosafety approval is typically required.
Q.What titer is supplied and how should MOI be chosen?
A.The vector is supplied at >1E+9 TU/mL functional titer, stated as a minimum. Calculate multiplicity of infection (MOI) from this value and the number of target cells, and optimize MOI empirically for each cell type, since transduction efficiency varies between cell lines and primary cells.
Q.How are transduced cells selected?
A.The cassette includes a puromycin resistance gene. Select transduced cells with a puromycin concentration determined by a kill curve on the parental cells, then maintain the stable pool under selection.
Q.Is expression constitutive or regulated?
A.Expression of the cassette is constitutive under the CMV promoter: no inducer or driver line is needed for the vector itself, and expression persists in daughter cells after integration. The Cre it delivers then acts on the partner element you supply: a loxP-flanked or DIO target allele.
Q.How should the vector be stored and handled?
A.Store at -80°C; avoid repeated freeze-thaw cycles. Ships on dry ice.

Can't find the lentiviral construct you need, or want to adjust key design elements? Contact us to discuss custom LV design and optional add-ons.

Common customization requests

  • Insert / payload: replace the gene/sequence, swap to a different isoform, add mutations, or optimize cloning features.
  • Expression design: change promoter (e.g., CMV/EF1α/PGK), add enhancers, or adjust regulatory elements.
  • Reporters: add/swap GFP/RFP/mCherry/luciferase (single or dual reporters where applicable).
  • Selection markers: add/swap puromycin/blasticidin/neomycin or fluorescent selection options.
  • Vector format: switch between OE, shRNA, CRISPR (sgRNA/Cas systems), or control vectors (where supported).

Add-ons you can request

  • Control viruses: empty vector, non-targeting shRNA, reporter-only controls, or matched backbone controls.
  • Packaging / format: concentration options, aliquoting, or custom fill volume for screening workflows.
  • Documentation: construct map/sequence confirmation package (as available) and batch documentation.

What to include in your request

  • Target cell type/model (cell line or primary cells) and intended readout (reporter, knockdown, OE, etc.)
  • Insert sequence (FASTA) or reference ID, plus any required tags/mutations
  • Promoter, reporter, and selection marker preferences
  • Desired scale and preferred format (aliquots / concentration requests)

Email us at support@biohippo.com or use the Talk to a Scientist request form.

Koo J, Seong CS, Parker RE, Herrera A, Dwivedi B, Arthur RA, et al. (2024) Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer. Cancer Res, 84(22), 3761-3771. 10.1158/0008-5472.CAN-23-2631

Jin R, Liu B, Liu X, Fan Y, Peng W, Huang C, et al. (2021) Leflunomide Suppresses the Growth of LKB1-Inactivated Tumors in the Immune-Competent Host and Attenuates Distant Cancer Metastasis. Mol Cancer Ther, 20(2), 274-283. 10.1158/1535-7163.MCT-20-0567

Koo J, Seong CS, Parker RE, Dwivedi B, Arthur RA, Dinasarapu AR, et al. (2023) Live-cell invasive phenotyping uncovers the ALK2/BMP6 iron homeostasis pathway as a therapeutic vulnerability in LKB1-mutant lung cancer. bioRxiv. 10.1101/2023.06.14.544941

Get a Quote

Please use this form for bulk quantity requests or customized products.

Contact Information

Product Information

Try Celltrypse Free – Request Your Sample Today

Experience the power of Celltrypse™, c-LEcta's innovative enzyme solution for gentle and efficient cell dissociation. Request your free sample and discover a superior alternative for your cell culture workflows.

Try Celltrypse Free – Request Your Sample Today

Try Celltrypse Free – Request Your Sample Today

Experience the power of Celltrypse™, c-LEcta's innovative enzyme solution for gentle and efficient cell dissociation. Request your free sample and discover a superior alternative for your cell culture workflows.

Try Celltrypse Free – Request Your Sample Today